AIM ImmunoTech Inc.
Symbol: AIM (NYSE)
2.58
▼ (-0.39%) -0.010
Company Description:
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Key Stats
- Today's Open: $2.59
- Today's High: $2.615
- Today's Low: $2.536
- Today's Volume: 12.32K
- Yesterday Close: $2.59
- Yesterday High: $2.63
- Yesterday Low: $2.46
- Yesterday Volume: 74.27K
- Last Min Volume: 102
- Last Min High: $2.58
- Last Min Low: $2.563
- Last Min VWAP: $2.577
Company Profile
- Name: AIM ImmunoTech Inc.
- Website: https://www.aimimmuno.com
- Listed Date: 1995-11-02
- Location: OCALA, FL
- Market Status: Active
- CIK Number: 0000946644
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $7.02M
- Round Lot: 100
- Outstanding Shares: 2.71M
- Asset Type: CS
RECENT FILINGS FOR AIM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | 10-Q | View |
| 2025-07-31 | 8-K | View |
| 2025-07-30 | 424B5 | View |
| 2025-07-28 | EFFECT | View |
| 2025-07-28 | 8-K | View |
| 2025-07-24 | CORRESP | View |
| 2025-07-24 | CORRESP | View |
| 2025-07-22 | S-1/A | View |
| 2025-07-21 | 4 | View |
| 2025-07-15 | S-8 | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-15 | S-1/A | View |
| 2025-07-03 | EFFECT | View |
| 2025-06-30 | CORRESP | View |
| 2025-06-27 | CORRESP | View |
| 2025-06-27 | S-3/A | View |
| 2025-06-20 | 8-K | View |
| 2025-06-16 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-12 | 8-K | View |
Latest News on AIM